To address this, we examined the association between E2F4 activity and neoadjuvant therapy response across different subgroupings of breast cancer, including ER status (Fig. 2a), tumor stage (Fig. 2b), and molecular subtype (Fig. 2c). The gene discussed is ESR1; the disease is breast cancer.